William Blair Investment Management LLC Purchases New Shares in Stevanato Group S.p.A. (NYSE:STVN)

William Blair Investment Management LLC acquired a new position in shares of Stevanato Group S.p.A. (NYSE:STVNFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 47,065 shares of the company’s stock, valued at approximately $1,026,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Van Berkom & Associates Inc. acquired a new position in shares of Stevanato Group in the fourth quarter valued at about $39,000. PNC Financial Services Group Inc. grew its position in shares of Stevanato Group by 1,457.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after purchasing an additional 5,291 shares in the last quarter. US Bancorp DE increased its holdings in shares of Stevanato Group by 17.9% during the fourth quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after purchasing an additional 1,295 shares during the period. Marco Investment Management LLC acquired a new stake in shares of Stevanato Group in the fourth quarter valued at approximately $203,000. Finally, Hardy Reed LLC boosted its stake in shares of Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after buying an additional 840 shares during the period.

Stevanato Group Trading Down 0.1 %

STVN opened at €21.74 ($23.63) on Thursday. The company has a market cap of $6.58 billion, a P/E ratio of 46.26, a PEG ratio of 7.18 and a beta of 0.60. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is €21.08 and its 200-day moving average is €20.59. Stevanato Group S.p.A. has a 1-year low of €16.56 ($18.00) and a 1-year high of €33.49 ($36.40).

Stevanato Group (NYSE:STVNGet Free Report) last issued its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). The firm had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Equities research analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

STVN has been the topic of a number of recent research reports. William Blair restated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Morgan Stanley restated an “equal weight” rating and issued a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America upped their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Wolfe Research initiated coverage on shares of Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price on the stock. Finally, UBS Group cut their price target on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of €27.75 ($30.16).

View Our Latest Stock Analysis on STVN

About Stevanato Group

(Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.

Featured Stories

Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVNFree Report).

Institutional Ownership by Quarter for Stevanato Group (NYSE:STVN)

Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.